Cyr61 levels are increased in the bone marrow of patients with ALL, and increased Cyr61 contributes to ALL cell survival and decreases their chemosensitivity to cytarabine (Cao et al. 2019; Zhu et al. 2016). Here, CCN1 is linked to acute lymphoblastic leukemia.